The Short-term efficacy of a monoclonal antibody fragment (brolucizumab) for treating neovascular age-related macular degeneration
Aim. To evaluate the short-term efficacy of using a monoclonal antibody fragment (Brolucizumab) for treating neovascular age-related macular degeneration, depending on the morphometric parameters of the retina. Methods: This study included 48 patients (60 eyes) diagnosed with neovascular age-related...
Saved in:
Main Authors: | A. F. Yusupov (Author), M. Kh. Karimova (Author), S. A. Djamalova (Author), D. K. Makhkamova (Author), S. I. Abdullaeva (Author), M. A. Zakirkhodjaeva (Author), Khodjaeva Zilola (Author), D. A. Rakhimova (Author) |
---|---|
Format: | Book |
Published: |
Ukrainian Society of Ophthalmologists,
2024-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration
by: Alaa Din Abdin, et al.
Published: (2022) -
Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular age‐related macular degeneration
by: Nadia Zakaria, et al.
Published: (2022) -
Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
by: Nicola Ferrante, et al.
Published: (2022) -
Anatomical and functional responses to single brolucizumab injection in neovascular age-related macular degeneration patients not responding to antiangiogenics: a case series
by: Silvio Zuccarini, et al.
Published: (2022) -
Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
by: Lorenzo Ferro Desideri, et al.
Published: (2023)